Danne Thomas, Råstam Jacob, Odendahl Rainer, Näke Andrea, Schimmel Ulf, Szczepanski Rüdiger, Moeller Johannes, Deiss Dorothea
Kinderkrankenhaus auf der Bult, Hannover, Germany.
Pediatr Diabetes. 2007 Oct;8(5):278-85. doi: 10.1111/j.1399-5448.2007.00261.x.
Preprandial insulin injection in preschool children is complicated by irregular eating habits. Postprandial injection of rapid-acting insulin analogs such as insulin aspart (IAsp) offers the convenience of adjusting insulin dose to match food consumed. This trial compared safety and efficacy - including parental treatment satisfaction - of two basal-bolus regimens [IAsp plus Neutral Protein Hagedorn (NPH) insulin vs. regular human insulin (HI) plus NPH] in preschool children with type 1 diabetes.
This study is a randomized, 12-wk, crossover trial comparing IAsp and regular HI in 26 children (17 boys and 9 girls; age: 2.4-6.9 yr). Regular HI was injected 30 min before and IAsp after or shortly before meals. Treatment satisfaction was assessed by a modified version of the WHO Diabetes Treatment Satisfaction Questionnaire (DTSQ-M).
Glycemic control for IAsp treatment was not different from that for regular HI treatment as assessed by mean postprandial blood glucose increment (IAsp vs. regular HI: 2.0 vs. 1.6 mmol/L), fructosamine (300 vs. 302 micromol/L), and hemoglobin A(1c) (HbA(1c)) (7.7 vs. 7.6%). The relative risk of hypoglycemia was not significantly different [relative risk for IAsp/regular HI (95% CI): 1.06 (0.96-1.17), p = 0.225]. Mean total daily insulin dose (0.7 U/kg) remained constant throughout the trial with both treatments. The DTSQ-M score tended to be better for IAsp and reached statistical significance regarding the parental satisfaction with continuing IAsp treatment (p < 0.05).
In preschool children, a basal-bolus treatment scheme with postprandial IAsp as bolus insulin was equally effective and safe compared with preprandial regular HI, although the parents showed a preference for the IAsp treatment.
学龄前儿童餐前注射胰岛素会因饮食习惯不规律而变得复杂。餐后注射速效胰岛素类似物如门冬胰岛素(IAsp)可方便地根据所摄入食物调整胰岛素剂量。本试验比较了两种基础 - 餐时胰岛素治疗方案[IAsp加中性鱼精蛋白锌胰岛素(NPH)与常规人胰岛素(HI)加NPH]在1型糖尿病学龄前儿童中的安全性和有效性,包括家长对治疗的满意度。
本研究是一项随机、为期12周的交叉试验,比较了26名儿童(17名男孩和9名女孩;年龄:2.4 - 6.9岁)使用IAsp和常规HI的情况。常规HI在餐前30分钟注射,IAsp在餐后或进餐前不久注射。通过世界卫生组织糖尿病治疗满意度问卷(DTSQ - M)的修订版评估治疗满意度。
通过餐后平均血糖增加值(IAsp与常规HI:2.0与1.6 mmol/L)、果糖胺(300与302 μmol/L)和糖化血红蛋白A1c(HbA1c)(7.7%与7.6%)评估,IAsp治疗的血糖控制与常规HI治疗无异。低血糖的相对风险无显著差异[IAsp/常规HI的相对风险(95%CI):1.06(0.96 - 1.17),p = 0.225]。两种治疗在整个试验期间平均每日胰岛素总剂量(0.7 U/kg)均保持不变。DTSQ - M评分IAsp倾向于更好,且在家长对继续使用IAsp治疗的满意度方面达到统计学显著差异(p < 0.05)。
在学龄前儿童中,与餐前常规HI相比,采用餐后IAsp作为餐时胰岛素的基础 - 餐时治疗方案同样有效且安全,尽管家长更倾向于IAsp治疗。